4basebio inks supply deal with Italy's Neomatrix

Synthetic DNA biotechnology specialist 4basebio announced a product supply agreement with Neomatrix on Thursday, which it described as an Italian biotech focussed on personalised cancer immunotherapies.

4basebio
02 May 2024 17:20:13

Source: Sharecast

The AIM-traded firm said the agreement aimed to develop a personalised cancer therapy using its proprietary ‘hpDNA’.

As part of the agreement, 4basebio would supply clinical and preclinical DNA materials for Neomatrix's neoantigen cancer vaccine programme.

The programme was scheduled to begin enrolling patients early next year.

Neomatrix would have access to 4basebio's DNA products, including hpDNA and ‘oeDNA’.

The key component in Neomatrix's immunotherapy cancer treatment would be the personalised, clinical-grade DNA products, which would be manufactured and supplied by 4basebio.

“We are delighted to be working with Neomatrix in the delivery of neoantigen cancer vaccines,” said chief executive and chief scientific officer, Dr Heikki Lanckriet.

“4basebio’s DNA products offer significant advantages both in terms of performance and the time required to manufacture a personalised vaccine, which is particularly relevant where needle to needle time is paramount to clinical outcome.”

At 0803 BST, shares in 4basebio were up 1.35% at 562.5p.

Reporting by Josh White for Sharecast.com.

Transferring your account

Transfer your existing ISAs and Share Dealing Accounts and you could save money. In order to transfer, log in to your existing account and complete the online application form. We’ll do the rest for you. It’s free to transfer (we will not charge you). Please check your current provider to see if they have any charges for transferring.

Transfer to us

N/A

Isin: N/A

Exchange: N/A

Sell:

N/A

Buy:

N/A

Change:

Date:

Prices delayed by at least 15 minutes

Compare our accounts

Whether you're looking for a Share Dealing Account, Stocks and Shares ISA or a Self-Invested Personal Pension (SIPP), we've got an account to suit your needs.

View our accounts

Bank of Scotland is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

Bank of Scotland Share Dealing Service is operated by Halifax Share Dealing Limited. Halifax Share Dealing Limited. Registered in England and Wales No. 3195646. Registered Office: Trinity Road, Halifax, West Yorkshire HX1 2RG. Authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.